Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous mesenchymal stem cell therapy in amyotrophic lateral sclerosis
IRCT20160809029275N2Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jun 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous mesenchymal stem cells in amyotrophic lateral sclerosis (ALS), sponsored by Mashhad University of Medical Sciences. Primary endpoints: ALSFRS-R evaluation, Forced vital capacity and 5 more. Started Jun 2020; status: completed.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on IRCT20160809029275N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160809029275N2.